Aspire Private Capital’s ADMA Biologics ADMA Stock Holding History

Aspire Private Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200	Closed	-$716	–	707
2023 Q3	$716	Buy	+200	New	+$770	﹤0.01%	620

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Aspire Private Capital's ADMA Position: Q4 2023 in Review

Aspire Private Capital sold out of ADMA Biologics (ADMA) in Q4 2023, closing a stake of 200 shares — an estimated $716 sold.

Aspire Private Capital first reported a position in ADMA in Q3 2023 and held it in 1 quarter. The position peaked at $716 in Q3 2023. 184 funds tracked by Wall St. Rank hold ADMA as of Q4 2023.

Aspire Private Capital reported no remaining ADMA Biologics position as of Q4 2023 after selling out during the quarter.
Aspire Private Capital sold 200 ADMA Biologics shares in Q4 2023, an estimated $716.
Aspire Private Capital first reported a position in ADMA Biologics in Q3 2023 and held it in 1 quarter.
Aspire Private Capital's ADMA Biologics position peaked at $716 in Q3 2023.
184 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2023.

Based on Aspire Private Capital's 13F filing for Q4 2023, filed 1 Feb 2024.